Biotech’s Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

PR Newswire

NEW YORK, Nov. 16, 2026 /PRNewswire/ — Biotech Today News Commentary – Clinical and regulatory news moved several drug developers on a down day for the broader market. The S&P 500 fell 1.92% to 7,416.59 and the Nasdaq Composite dropped 2.49% to 24,509.76 on Monday, according to CNBC’s closing report. In bladder cancer, one of the areas in the spotlight, Research and Markets projects the global bladder cancer drugs market will grow from USD 6.89 billion in 2026 to USD 11.84 billion by 2032, a compound annual growth rate of 9.41%. Active Companies from around the markets with current developments this week include: CG Oncology, Inc. (NASDAQ: CGON), Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Summit Therapeutics Inc. (NASDAQ: SMMT), Aclaris Therapeutics, Inc. (NASDAQ: ACRS).

Biotech Today Logo

A Phase 3 Win, a Gene Therapy Update, an FDA Letter and a Phase 2 Miss

The day’s biotech news ran in both directions. A late-stage bladder cancer trial met its primary endpoint and an inherited heart disease gene therapy reported interim data, while a lung cancer application received an FDA complete response letter and an atopic dermatitis antibody missed its Phase 2 goals. Summit Therapeutics’ shares fell 16.5% after its FDA decision, according to the Associated Press.

In other industry developments and happenings in the market this week include:

CG Oncology, Inc. (NASDAQ: CGON) reported that its Phase 3 PIVOT-006 registrational trial of adjuvant intravesical cretostimogene met its primary endpoint in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer measuring 3 cm or less following complete tumor resection. Cretostimogene reduced the risk of recurrence by 68% compared with the control arm, with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001).

The trial enrolled 367 patients across approximately 90 sites in the United States and Canada. The company plans to submit a biologics license application supported by the PIVOT-006 data in the second quarter of 2027, and the topline results are scheduled to be presented at the Society of Urologic Oncology Annual Meeting on December 2, 2026. Cretostimogene is an investigational candidate.

Lexeo Therapeutics, Inc. (NASDAQ: LXEO) reported positive interim Phase I/II data for LX2020, its investigational gene therapy for PKP2 arrhythmogenic cardiomyopathy. Participants in the high-dose cohorts achieved an 80% mean reduction in non-sustained ventricular tachycardia and a 44% mean reduction in premature ventricular contractions at latest assessment. Ten participants have been dosed, and as of the October 15, 2026 data cutoff, nine had reached at least 12 months of follow-up.

Lexeo also said the FDA is open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020. The update was released together with the company’s third quarter 2026 financial results.

Summit Therapeutics Inc. (NASDAQ: SMMT) said the FDA issued a complete response letter for its biologics license application for ivonescimab combined with platinum-based chemotherapy in previously treated EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer. According to the company, the FDA concluded that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival improvement.

The application was based on the global Phase III HARMONi trial, in which ivonescimab plus chemotherapy showed a statistically significant improvement in progression-free survival, with a hazard ratio of 0.52, while overall survival showed a positive trend without reaching statistical significance, according to the company’s SEC filings.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported that its Phase 2 ADMIRATION trial of bosakitug (ATI-045), an investigational anti-TSLP monoclonal antibody, did not achieve its primary or secondary endpoints in patients with moderate-to-severe atopic dermatitis. The primary endpoint measured the percent change from baseline in Eczema Area and Severity Index score at week 24.

The company said pharmacodynamic results showed robust TSLP target engagement and downregulation of Th1-, Th2- and Th17-related immune-activation biomarkers, and that bosakitug was generally well tolerated. Aclaris also reported initiating the Phase 2b ALPHA trial of modzatinib in patients with moderate-to-severe lichen planus.

Track the Signals Before the Crowd

The best positioning happens before the crowd catches on. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they form, so you see attention building instead of chasing it. Watch it live at eagle-eye.dev.

Contact Information:

biotech-today.com

Media Contact: info@biotech-today.com

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a market commentary and is not a paid advertisement. It is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

This article is being distributed by Biotech Today, which is wholly owned and operated by Market Equities Limited (“MEL”), a company incorporated under the laws of Ireland. This is an independent market commentary published on a non-paid basis. MEL has not been paid any fee by any company mentioned in this article for the production or distribution of this article.

MEL and its owners, operators, directors, and affiliates may hold positions in securities of companies mentioned in this article, and reserve the right to, and will, buy and sell shares of any company mentioned in this article at any time without further notice, commencing immediately and ongoing, in the open market, through private placements, and/or through other investment vehicles. There may also be third parties who hold shares of the companies mentioned and may liquidate their shares, which could have a negative effect on the price of the stock.

Information in this article was obtained from sources believed to be reliable, including company news releases, regulatory filings and published market reports, but it is not guaranteed by us to be accurate. Market figures are as of the close of trading on November 16, 2026 unless otherwise stated, and are attributed to the reports cited. Individuals should assume that all information contained in this publication is not trustworthy unless verified by their own independent research. Market-size figures are third-party projections. Always consult a licensed investment professional before making any investment decision. Be extremely careful: investing in securities carries a high degree of risk, and you may lose some or all of your investment.

Cautionary Note Regarding Clinical and Regulatory Information. The product candidates discussed in this article are investigational, have not been approved by the U.S. Food and Drug Administration or any other regulatory authority for the uses described, and have not been shown to be safe or effective for those uses. Topline and interim results are preliminary, may change as data mature, and may not be predictive of final results or of regulatory outcomes. Planned submissions, presentations and study timelines are the companies’ own expectations.

Eagle Eye Disclosure. Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article, and this reference constitutes promotion of an affiliated product. Eagle Eye is not a broker-dealer, and nothing in the platform or in this article is financial, investment, tax, or legal advice. Data provided in the platform is for informational purposes only and may be delayed. Always do your own research before making any investment decision.

Forward-Looking Statements: This publication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements made by the companies mentioned in their own news releases and filings. Such statements are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “targets” or “projected”, and are subject to risks and uncertainties that could cause actual results to differ materially. Readers should review each company’s filings with the Securities and Exchange Commission and, where applicable, Canadian securities regulators, and should not place undue reliance on such statements. The forward-looking statements in this publication are made as of the date hereof and MEL undertakes no obligation to update such statements.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biotechs-monday-split-two-trial-wins-one-trial-miss-and-an-fda-rejection-302941159.html

SOURCE Biotech Today

About The Author